texas oncology more breakthroughs. more victories
Some of our cancer centers may have important notifications found on the location page. View More Important Notifications x
Request an Appointment

Panhandle Clinical Trials

Texas Oncology cancer centers in the Texas Panhandle participate in a wide range of clinical trials and ground-breaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the Texas Panhandle area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the Texas Panhandle area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks of Participating in Clinical Trials

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the Texas Panhandle area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Clinical Trial Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the Texas Panhandle area and talk to you doctor to determine which clinical trial is right for you.

Anal Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Biliary Cancer

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Bladder Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Blood Cancer

Title: Ph2 Sub Mosunetuzumab B-cell malig View

Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Indication: Blood Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Breast Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Title: Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD) View

Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: Observational Study of patients initiating T-Dxd in HER2+ unresectable mBC (RESPOND) View

Description: A multi-center multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+ and HER2-low unresectable and/or metastatic breast cancer (DESTINY BREAST- RESPOND) (D9673R00025)

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Cervical Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: Ph2 SKB264 + Pembro in Select Solid Tumors View

Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)

Indication: Cervical Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Colon Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Endometrial Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Esophageal Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Fallopian Tube Cancer

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Gall Bladder Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Gastric Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Head and Neck Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Hematologic

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Indication: Hematologic

Location: Texas Oncology-Amarillo Cancer Center

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Kidney Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Leukemia

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Liver Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Lung Cancer

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: Ph3 Dato-DXd + Durva + Carbo v. Pembro + plat chemo in 1L mNSCLC View

Description: A Phase III Randomised Open-label Multicentre Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: Ph3 SGN-B6A vs docetaxel NSCLC View

Description: A randomized phase 3 open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer (SGN-B6A-002)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Lymphomas

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: Ph2 Sub Mosunetuzumab B-cell malig View

Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Indication: Lymphomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Melanoma

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Mesothelioma

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)

Indication: Mesothelioma

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Myelodysplastic Syndrome

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Myelomas

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Ovarian Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: Ph2 SKB264 + Pembro in Select Solid Tumors View

Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)

Indication: Ovarian Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Pancreatic Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Peritoneal Cancer

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Prostate Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: Ph2 SKB264 + Pembro in Select Solid Tumors View

Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)

Indication: Prostate Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Rectal Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Renal Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Skin Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Solid Tumors

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Testicular Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Thyroid Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Urothelial Cancer

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II/III

Title: Ph2 SKB264 + Pembro in Select Solid Tumors View

Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)

Indication: Urothelial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Uterine Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Vulvar Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Waldenström macroglobulinemia

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Texas Oncology-Amarillo Cancer Center

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Indication: Hematologic

Location: Texas Oncology-Amarillo Cancer Center

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: Ph2 Sub Mosunetuzumab B-cell malig View

Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Indication: Blood Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Title: Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD) View

Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: Observational Study of patients initiating T-Dxd in HER2+ unresectable mBC (RESPOND) View

Description: A multi-center multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+ and HER2-low unresectable and/or metastatic breast cancer (DESTINY BREAST- RESPOND) (D9673R00025)

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: Ph2 SKB264 + Pembro in Select Solid Tumors View

Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)

Indication: Cervical Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: Ph3 Dato-DXd + Durva + Carbo v. Pembro + plat chemo in 1L mNSCLC View

Description: A Phase III Randomised Open-label Multicentre Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: Ph3 SGN-B6A vs docetaxel NSCLC View

Description: A randomized phase 3 open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer (SGN-B6A-002)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: Ph2 Sub Mosunetuzumab B-cell malig View

Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Indication: Lymphomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)

Indication: Mesothelioma

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: Ph2 SKB264 + Pembro in Select Solid Tumors View

Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)

Indication: Ovarian Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: Ph2 SKB264 + Pembro in Select Solid Tumors View

Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)

Indication: Prostate Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II/III

Title: Ph2 SKB264 + Pembro in Select Solid Tumors View

Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)

Indication: Urothelial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

No Phase

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Indication: Hematologic

Location: Texas Oncology-Amarillo Cancer Center

Phase I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I

Phase I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)

Indication: Endometrial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)

Indication: Mesothelioma

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Amarillo Cancer Center

Phase: I/II

Phase II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: Ph2 Sub Mosunetuzumab B-cell malig View

Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Indication: Blood Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: Ph2 SKB264 + Pembro in Select Solid Tumors View

Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)

Indication: Cervical Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: Ph2 Sub Mosunetuzumab B-cell malig View

Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Indication: Lymphomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: Ph2 SKB264 + Pembro in Select Solid Tumors View

Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)

Indication: Ovarian Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: Ph2 SKB264 + Pembro in Select Solid Tumors View

Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)

Indication: Prostate Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: Ph2 SKB264 + Pembro in Select Solid Tumors View

Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)

Indication: Urothelial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Phase II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II/III

Phase III

Title: Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD) View

Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: Ph3 Dato-DXd + Durva + Carbo v. Pembro + plat chemo in 1L mNSCLC View

Description: A Phase III Randomised Open-label Multicentre Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Title: Ph3 SGN-B6A vs docetaxel NSCLC View

Description: A randomized phase 3 open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer (SGN-B6A-002)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: III

Phase IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: Observational Study of patients initiating T-Dxd in HER2+ unresectable mBC (RESPOND) View

Description: A multi-center multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+ and HER2-low unresectable and/or metastatic breast cancer (DESTINY BREAST- RESPOND) (D9673R00025)

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV